Clinical and dosimetric predictors of radiation-induced esophageal toxicity. 1999

P D Maguire, and G S Sibley, and S M Zhou, and T A Jamieson, and K L Light, and P A Antoine, and J E Herndon, and M S Anscher, and L B Marks
Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA.

OBJECTIVE To evaluate the incidence, severity, and clinical/dosimetric predictors of acute and chronic esophageal toxicities in patients with non-small cell lung cancer (NSCLC) treated with high-dose conformal thoracic radiation. METHODS Ninety-one patients with localized NSCLC treated definitively with high-dose conformal radiation therapy (RT) at Duke University Medical Center (DUMC) were reviewed. Patient characteristics were as follows: 53 males and 38 females; median age 64 yr (range 46-82); stage I--16, II--3, IIIa--40, IIIb--30, X--2; dysphagia pre-RT--6 (7%). Treatment parameters included: median corrected dose-78.8 Gy (range 64.2-85.6); BID fractionation-58 (64%); chemotherapy-43 (47%). Acute and late esophageal toxicities were graded by RTOG criteria. Using 3D treatment planning tools, the esophagus was contoured in a uniform fashion, the 3D dose distribution calculated (with lung density correction), and the dose-volume (DVH) and dose-surface histograms (DSH) generated. At each axial level, the percentage of the esophageal circumference at each dose level was calculated. The length of circumferential esophagus and the maximum circumference treated to doses >50 Gy were assessed. Patient and treatment factors were correlated with acute and chronic esophageal dysfunction using univariate and multivariate logistic regression analyses. RESULTS There were no acute or late grade 4 or 5 esophageal toxicities. Ten of 91 patients (11%) developed grade 3 acute toxicity. On univariate analysis of clinical parameters, both dysphagia pre-RT (p = 0.10) and BID fractionation (p = 0.11) tended toward significantly predicting grade 3 acute esophagitis. None of the dosimetric parameters analyzed significantly predicted for grade 3 acute esophagitis. Twelve of 66 assessable patients (18%) developed late esophageal toxicity. Of the clinical parameters analyzed, only dysphagia pre-RT (p = 0.06) tended toward significantly predicting late esophageal toxicity. On univariate analyses, the effects of percent organ volume treated >50 Gy (p = 0.05), percent surface area treated >50 Gy (p = 0.05), length of 100% circumference treated >50 Gy (p = 0.04), and maximum percent of circumference treated >80 Gy (p = 0.01) significantly predicted for late toxicity of all grades. On multivariate analysis, percent organ volume treated >50 Gy (p = 0.02) and maximum percent of circumference treated >80 Gy (p = 0.02) predicted for late toxicity. CONCLUSIONS Late esophageal toxicity following aggressive, high-dose conformal radiotherapy is common but rarely severe. Dosimetric variables addressing the longitudinal and circumferential character of the esophagus have biologic rationale and are predictive of late toxicity. Further studies are needed to assess whether these parameters are better predictors than those derived from traditional DVHs.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011832 Radiation Injuries Harmful effects of non-experimental exposure to ionizing or non-ionizing radiation in VERTEBRATES. Radiation Sickness,Radiation Syndrome,Injuries, Radiation,Injury, Radiation,Radiation Injury,Radiation Sicknesses,Radiation Syndromes,Sickness, Radiation,Sicknesses, Radiation,Syndrome, Radiation,Syndromes, Radiation
D011879 Radiotherapy Dosage The total amount of radiation absorbed by tissues as a result of radiotherapy. Dosage, Radiotherapy,Dosages, Radiotherapy,Radiotherapy Dosages
D002289 Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy. Carcinoma, Non-Small Cell Lung,Non-Small Cell Lung Cancer,Non-Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinoma,Nonsmall Cell Lung Cancer,Carcinoma, Non Small Cell Lung,Carcinomas, Non-Small-Cell Lung,Lung Carcinoma, Non-Small-Cell,Lung Carcinomas, Non-Small-Cell,Non Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinomas
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D003680 Deglutition Disorders Difficulty in SWALLOWING which may result from neuromuscular disorder or mechanical obstruction. Dysphagia is classified into two distinct types: oropharyngeal dysphagia due to malfunction of the PHARYNX and UPPER ESOPHAGEAL SPHINCTER; and esophageal dysphagia due to malfunction of the ESOPHAGUS. Dysphagia,Swallowing Disorders,Esophageal Dysphagia,Oropharyngeal Dysphagia,Deglutition Disorder,Disorders, Deglutition,Dysphagia, Esophageal,Dysphagia, Oropharyngeal,Swallowing Disorder
D004935 Esophageal Diseases Pathological processes in the ESOPHAGUS. Disease, Esophageal,Diseases, Esophageal,Esophageal Disease
D004941 Esophagitis INFLAMMATION, acute or chronic, of the ESOPHAGUS caused by BACTERIA, chemicals, or TRAUMA. Esophagitides

Related Publications

P D Maguire, and G S Sibley, and S M Zhou, and T A Jamieson, and K L Light, and P A Antoine, and J E Herndon, and M S Anscher, and L B Marks
January 2011, Tumori,
P D Maguire, and G S Sibley, and S M Zhou, and T A Jamieson, and K L Light, and P A Antoine, and J E Herndon, and M S Anscher, and L B Marks
May 2005, World journal of gastroenterology,
P D Maguire, and G S Sibley, and S M Zhou, and T A Jamieson, and K L Light, and P A Antoine, and J E Herndon, and M S Anscher, and L B Marks
February 2005, International journal of radiation oncology, biology, physics,
P D Maguire, and G S Sibley, and S M Zhou, and T A Jamieson, and K L Light, and P A Antoine, and J E Herndon, and M S Anscher, and L B Marks
July 2017, Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al],
P D Maguire, and G S Sibley, and S M Zhou, and T A Jamieson, and K L Light, and P A Antoine, and J E Herndon, and M S Anscher, and L B Marks
October 2002, International journal of radiation oncology, biology, physics,
P D Maguire, and G S Sibley, and S M Zhou, and T A Jamieson, and K L Light, and P A Antoine, and J E Herndon, and M S Anscher, and L B Marks
January 2021, Practical radiation oncology,
P D Maguire, and G S Sibley, and S M Zhou, and T A Jamieson, and K L Light, and P A Antoine, and J E Herndon, and M S Anscher, and L B Marks
January 2024, Frontiers in oncology,
P D Maguire, and G S Sibley, and S M Zhou, and T A Jamieson, and K L Light, and P A Antoine, and J E Herndon, and M S Anscher, and L B Marks
January 2021, Advances in radiation oncology,
P D Maguire, and G S Sibley, and S M Zhou, and T A Jamieson, and K L Light, and P A Antoine, and J E Herndon, and M S Anscher, and L B Marks
January 2009, Acta oncologica (Stockholm, Sweden),
P D Maguire, and G S Sibley, and S M Zhou, and T A Jamieson, and K L Light, and P A Antoine, and J E Herndon, and M S Anscher, and L B Marks
August 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology,
Copied contents to your clipboard!